SANIONA Aktie

 

WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ), Wednesday announced a global license agreement with Denmark-based Saniona to obtain exclusive worldwide rights to develop SAN2355, a preclin......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential......

NL0015001BF4 NL0015001OI1 NO0005806802 NO0006390301 NO0010015175 NO0010098247 NO0010257728 NO0010360266 NO0010692130 NO0010713936 NO0010892359 NO0010894231 NO0010963275 NO0011002651 NO0012697715 NO0013119255 NO0013186460 NO0013461350 NZFAPE0001S2 NZGNEE0001S7 SE0000106205 SE0000107203 SE0000112252 SE0000171886 SE0000188518 SE0000195810 SE0000233934 SE0000648669 SE0000671745 SE0000683484 SE0000949331 SE0001057910 SE0001075102 SE0001161654 SE0001552357 SE0001860511 SE0001863291 SE0002110064 SE0002148817 SE0002190926 SE0002485979 SE0003273531 SE0003756758 SE0003815604 SE0003917798 SE0003943620 SE0004210854 SE0004898799 SE0005101003 SE0005162880 SE0005250719 SE0005308558 SE0005392537 SE0005454873 SE0005624756 SE0005768124 SE0005794617 SE0005878741 SE0005881786 SE0005933082 SE0005999836 SE0006091997 SE0006261046 SE0006343745 SE0006421871 SE0006510335 SE0007045414 SE0007074166 SE0007075247 SE0007100359 SE0007158118 SE0007413455 SE0007438577...

Saniona has taken a step forward within its epilepsy program by initiating the scale-up and manufacturing of toxicology batches for SAN2219. This move propels the program toward clinical studies, targeted for the first half of 2026. BioStock reached out to Chief Scientific Officer, Karin Sandager Nielsen, for a comment. Read the full interview with Karin Sandager Nielsen at biostock.se: https://www.biostock.se/en/2025/03/sanionas-cso-we-are-on-track-with-san2219/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/...

Saniona has secured guarantee commitments for its ongoing TO4 warrant exercise, running from March 18 to April 1, which could raise up to SEK 115 million. The board and CEO Thomas Feldthus have also pledged full participation, signaling strong confidence in the company's future direction. We reached out to Feldthus for insight into why he and the board are committing fully to the initiative. Read the full interview with Thomas Feldthus at biostock.se: https://www.biostock.se/en/2025/03/sanionas-ceo-the-to4-proceeds-give-us-flexibility-to-secure-the-best-deals/ This is a press release...

Saniona has appointed Pierandrea Muglia, M.D., as Chief Medical Officer, bringing over three decades of expertise from large international pharmaceutical companies, biotech and neuroscience research. A board member since 2023, Muglia has seen Saniona's pipeline grow and its partnerships, like the $610 million deal with Acadia Pharmaceuticals, thrive. Now, he'll steer the company's clinical and regulatory efforts as it prepares three candidates for phase II trials. We talked with Muglia to explore his visions. Read the full interview at biostock.se: https://www.biostock.se/en/2025/03/...

Saniona is advancing its treatments for epilepsy and neurological disorders, with SAN2355 – a selective epilepsy therapy – now in GMP-manufacturing and toxicology studies, aiming for a clinical trial application by late 2025. Meanwhile, Saniona and Acadia Pharmaceuticals has completed two phase I MAD cohorts for ACP-711, formerly SAN711, confirming its safety in healthy volunteers. In addition, from March 18 to April 1, 2025, Saniona's TO4 warrant program could raise up to SEK 188.4 million. We spoke with CEO Thomas Feldthus to learn more. Read the full interview with Thomas Feldthus at...